Literature DB >> 25962435

Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.

Xiaomin Gui1, Yong Zhang1,2, Jinlan Pan1, Huiying Qiu1, Jiannong Cen1, Yongquan Xue1, Suning Chen1, Hongjie Shen1, Li Yao1, Jun Zhang1, Yafang Wu1, Yan Chen1.   

Abstract

Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome (Ph) and BCR-ABL fusion genes. This study retrospectively analyzed 2381 CML patients with Ph chromosome confirmed by cytogenetics, Fluorescence in situ hybridization (FISH) or real-time quantitative polymerase chain reaction (Q-PCR). Among them, five CML patients without e13a2, e14a2 or e1a2 transcripts detected by Q-PCR were identified. DNA sequencing confirmed the fusion of BCR exon 14 and ABL exon 3. Case 1 reponded poorly to imatinib and achieved complete cytogenetic response (CCyR) after converting from imatinib to dasatinib. BCR-ABL transcripts were undetectable in cases after 2, 3 and 4 treated with imatinib after 6, 6 and 3 months, respectively, and in one patient who had undergone allogeneic hematopoietic stem cell transplantation after 4 months. Q-PCR may miss the detection of rare cases that are not covered by the primers used in Q-PCR, unless the proper primers are used.

Entities:  

Keywords:  Leukemia; TKIs; chronic; myeloid

Mesh:

Substances:

Year:  2015        PMID: 25962435     DOI: 10.3109/10428194.2015.1037751

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur P Patel; Graciela Nogueras Gonzalez; Rajyalakshmi Luthra; Rashmi Kanagal Shamanna; Koji Sasaki; Elias Jabbour; Carlos Guillermo Romo; Tapan M Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

2.  Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.

Authors:  Michele Massimino; Stefania Stella; Elena Tirrò; Maria Letizia Consoli; Maria Stella Pennisi; Adriana Puma; Silvia Rita Vitale; Chiara Romano; Valentina Zammit; Fabio Stagno; Francesco Di Raimondo; Livia Manzella
Journal:  Oncol Lett       Date:  2019-07-04       Impact factor: 2.967

3.  How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review.

Authors:  Lin-Hui Hu; Lian-Fang Pu; Dong-Dong Yang; Cui Zhang; Hui-Ping Wang; Yang-Yang Ding; Man-Man Li; Zhi-Min Zhai; Shudao Xiong
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

4.  Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts.

Authors:  Michele Massimino; Elena Tirrò; Stefania Stella; Livia Manzella; Maria Stella Pennisi; Chiara Romano; Silvia Rita Vitale; Adriana Puma; Cristina Tomarchio; Sandra Di Gregorio; Agostino Antolino; Francesco Di Raimondo; Paolo Vigneri
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.